Mealey's (July 7, 2020, 2:32 PM EDT) -- WASHINGTON, D.C. — A pharmaceutical company will pay more than $21 million to settle claims brought by the Securities and Exchange Commission that allege that the defendant violated provisions of the Foreign Corrupt Practices Act of 1977 (FCPA) when its Russian and Turkish subsidiaries engaged in schemes to pay government officials in those countries for favorable treatment for the company’s primary drug, Soliris, according to a cease-and-desist order filed by the SEC on July 2 (In the Matter of Alexion Pharmaceuticals Inc., No. 3-19852, SEC)....